
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
over 26 years ago
Selected Abstractsover 26 years ago
Continuing Pharmacy/Medical Education Quizover 26 years ago
Bibliographyover 26 years ago
Participating Facultyover 26 years ago
Introductionover 26 years ago
Critical Issues in the Management of Depressionover 26 years ago
Patient Compliance in Depressionover 26 years ago
Pharmacokinetics and Pharmacodynamics of Antidepressant Medicationsover 26 years ago
Improving Depression Treatment in Managed Primary Care Practices





